AstraZeneca - MIDAS


1 January, 2004 – AstraZeneca

AstraZeneca is one of the world's leading pharmaceutical companies with more than 58,000 employees worldwide. The company is focused on providing new and effective prescription medicines that make a real difference for patients.

It concentrates on important areas of medical need – cancer, cardiovascular, central nervous system, gastrointestinal, infection, pain control, and respiratory and inflammation. Backed by a strong research base and extensive commercial skills, AstraZeneca manufactures in 20 countries and sells in more than 100.

In the UK AstraZeneca has eight principal sites and employs 10,000 people. Each location has a clear sense of purpose and identity, together forming a strategic hub for global activities and complementing its strong presence in the key US market and our R&D headquarters based in Sweden.

AstraZeneca has two R&D centres of excellence in the UK, one at Alderley Park in Cheshire and one at Charnwood near Loughborough in Leicestershire. It also has a major manufacturing presence in Macclesfield, Cheshire, and another at Avlon, near Bristol, whilst near Luton in Bedfordshire is the base for UK-specific sales and marketing operations. In addition, individual functions with global responsibilities, such as International Sales and Marketing, Finance and Operations also have established headquarters in the UK.

The Shared Services project in AstraZeneca began in December 2000 to create a financial Shared Services Centre servicing 15 European countries, including countries traditionally seen as a challenge such as Italy and Germany.

The centre, which is based in West Didsbury in South Manchester and has 150 operational staff that speak 10 different languages was rolled out over a two year programme and is now fully operational delivering purchase to pay, order to cash, travel and expense management and general accounting to the UK, Ireland, Denmark, Norway, Finland, Italy, France, Netherlands, Belgium, Luxembourg, Austria, Switzerland, Germany, Portugal and Spain.

Erick Oswald, European Business Services Director, European Business Services, said: "We selected Manchester for our Shared Services operation because of the availability of multi-lingual staff and the close proximity of Manchester Airport.."

Source: AstraZeneca


< Back to the list

Leave a Reply